Deliberate release of biological agents

Anaesthesia

Volumn 57, Issue 11, 2002, Pages 1067-1082

  Sardesai, A M ^a,c   Brown, N M ^b   Menon, D K ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c PETERBOROUGH DISTRICT HOSPITAL   (United Kingdom)

Author keywords

Bioterrorism: Critical illness; deliberate release

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FURAZOLIDONE; GENTAMICIN; IMIPENEM; IMMUNOGLOBULIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RIFAMPICIN; SMALLPOX VACCINE; STEROID; STREPTOMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTIFICIAL VENTILATION; BACTERIUM; BIOLOGICAL WARFARE; BOTULISM; BRUCELLOSIS; CARDIOVASCULAR SURGERY; CHEMOPROPHYLAXIS; CHOLERA; CLINICAL FEATURE; CLINICAL TRIAL; CROSS INFECTION; DIAGNOSTIC TEST; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG INFORMATION; DRUG PENETRATION; ENDOCARDITIS; GASTROINTESTINAL INFECTION; HORSE DISEASE; HUMAN; INFECTION CONTROL; INHALATION; INTENSIVE CARE; INTENSIVE CARE UNIT; INTERNET; MEDICAL INFORMATION; MYCOTOXICOSIS; NONHUMAN; ORAL REHYDRATION THERAPY; PARENTERAL NUTRITION; PATIENT CARE; PLAGUE; PRACTICE GUIDELINE; PROTECTION; Q FEVER; REHYDRATION; REVIEW; SEIZURE; SKIN INFECTION; SMALLPOX; TULAREMIA; VIRUS ENCEPHALITIS;

BIOTERRORISM; DIAGNOSIS, DIFFERENTIAL; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; HUMANS; INFECTION; LABORATORY INFECTION; RARE DISEASES;

EID: 0036844592     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2044.2002.02828.x     Document Type: Review

References (54)

1. Derbes VJ. De Mussis and the great plague of 1348: a forgotten episode of bacteriological war. Journal of the American Medical Association 1996; 196: 59-62.
2. WHO. Health Aspects of Chemical and Biological Weapons. Geneva, Switzerland: World Health Organisation, 1970: 98-9.
3. Centers for Disease Control and Prevention, USA. Prepared list of biological agents. http://www.bt.cdc.gov/Agent/Agentlist.asp.
4. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. Journal of the American Medical Association 2002; 287: 2236-52.
5. Inglesby TV, Henderson DA, Bartlett JG, et al. Consensus Statement: Anthrax as a Biological weapon. Medical and Public health management. Journal of the American Medical Association 1999; 281: 1735-45.
6. Borio L, Frank D, Mani V, et al. Death due to bioterrorism-related inhalational anthrax: Report of two patients. Journal of the American Medical Association 2001; 286: 2554-9.
7. Mina B, Dym JP, Kuepper F, et al. Fatal inhalational anthrax with unknown source of exposure in a 61 year old woman in New York City. Journal of the American Medical Association 2002; 287: 8-62.
8. Dutz W, Saidi F, Kouhout E. Gastric anthrax with massive ascites. Gut 1970; 11: 352-4.
9. Public Health Laboratory Service - Communicable Disease Surveillance Centre. Interim guidelines for action in the event of deliberate release, Anthrax, Version 4. Issued by Communicable Disease Surveillance Centre, 1 November 2001. www.phls.co.uk/topics_az/anthrax/guidelines.pdf
10. Swartz MN. Recognition and management of anthrax - an update. New England Journal of Medicine 2001; 345: 1621-6.
11. Jernigan JA, Stephens DA, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerging Infectious Diseases 2001; 7: 933-44.
12. Madkour MM, Kasper DL. Brucellosis. In: Braunwald E, Fauci AS, Kasper DL et al., eds. Harrison's Principles of Internal Medicine, 15th edn. New York: McGraw-Hill 2001, 986-9.
13. Olle GJ, Canela SJ. An outbreak of Brucella melitensis infection by airborne transmission among laboratory workers. American Journal of Public Health 1987; 77: 335-8.
14. Tohme A, Hammond A, el Rassi B, Germanos-Haddad M, Ghayad E. Human Brucellosis. Retrospective studies of 63 cases in Lebanon. Presse Medicale 2001; 30: 1339-43.
15. Peery TM, Belter LF. Brucellosis and heart disease II. Fatal Brucellosis. American Journal of Pathology 1960; 36: 673-97.
16. Gotuzzo E, Carillo C, Guerra J, Llosa L. An evaluation of diagnostic methods for brucellosis - the value of bone marrow culture. Journal of Infectious Diseases 1986; 153: 122-5.
17. Young EJ. Serological diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of literature. Review of Infectious Diseases 1991; 13: 359-72.
18. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. Journal of the American Medical Association 1997; 278: 399-411.
19. Keles C, Bozbuga N, Sismanogle M, et al. Surgical treatment of Brucella endocarditis. Annals of Thoracic Surgery 2001; 19: 806-10.
20. Hadjinikolaou L, Triposkiadis F, Zairis M, et al. Successful management of Brucella melitensis endocarditis with combined medical and surgical approach. European Journal of Cardiothoracic Surgery 2001; 19: 806-10.
21. Keusch GT, Waldor MK. Cholera and other vibrioses. In: Braunwald E, Fauci AS, Kasper DL, et al., eds. Harrison's Principles of Internal Medicine, 15th edn. New York: McGraw-Hill 2001, 980-6.
22. Center for the Study of Bioterrorism and Emerging Infections. Bioterrorism agent fact sheet. Cholera/Vibrio Cholerae. http://bioterrorism.slu.edu/quick/cholera01.PDF.
23. Center for the Study of Bioterrorism and Emerging Infections. Bioterrorism agent fact sheet. Glanders/Burkholdera Mallei. http://bioterrorism.slu.edu/quick/cholera01.PDF.
24. Pollack M. Pseudomonas infection. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., eds. Harrison's Principles of Internal Medicine, 13th edn. New York: McGraw Hill, 1994, 671.
25. Srinivas A, Kraus CN, Deshazer D, et al. Brief report: Glanders in medical research microbiologist. New England Journal of Medicine 2001; 345: 256-8.
26. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: Medical and public health management. Working group on civilian biodefense. Journal of the American Medical Association 2000; 283: 81-90.
27. Public Health Laboratory Service - Communicable Disease Surveillance Centre. Interim Guidelines for Action in the Event of Deliberate Release, Plague (Issue 1/Version 4), Issued by Communicable Disease Surveillance Centre; 26 November 2001. http://www.phls.co.uk/topics_az/plague/plague_guidelines.pdf. guidelines.pdf.
28. Public Health Laboratory Service - Communicable Disease Surveillance Centre. Interim Guidelines for Action in the Event of Deliberate Release, Tularemia. (Version 1). Issued by Communicable Disease Surveillance Centre; 29 November 2001. http://www.phls.co.uk/topics_az/deliberate_release/pdf/tularemia_ guidelines.pdf.
29. Center for Civilian Biodefense Studies, John Hopkins University. Tularemia fact sheet. www.hopins-biodefense.org/pages/agents/agenttularemia.html.
30. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. Journal of the American Medical Association 2001; 285: 2763-73.
31. Marrie TJ. Coxiella burnetti (Q fever) pneumonia. Clinical Infectious Diseases 1995; 21: S253-64.
32. Smith DL, Wellings R, Walker C, et al. The chest X-ray in Q fever: a report of 69 cases from the 1989 West midlands outbreak. British Journal of Radiology 1991; 64: 1101-8.
33. Oddo M, Jolidon RM, Peter O, et al. Q fever pneumonia complicated by acute respiratory distress syndrome. Intensive Care Medicine 2001; 27: 615.
34. Tselentis Y, Gikas A, Kofteridis D, et al. Q fever in the Greek island of Crete: epidemiological, clinical and therapeutic data from 98 cases. Clinical Infectious Diseases 1995; 20: 1311-16.
35. Fenollar F, Fournier PE, Carrieri MP. Risk factor and prevention of Q fever endocarditis. Clinical Infectious Diseases 2001; 33: 312-16.
36. Henning KJ, Layton M. Bioterrorism APIC Text of Infection Control and Epidemiology. Washington, DC: Association for Professionals in Infection Control and Epidemiology, 2000. http://www.apic.org/bioterror/chapter124/pdf
37. Henderson DA, Inglesby TV, Bartlett JG et al. Smallpox as a biological weapon: medical and public health management - Working Group on Civilian Biodefense. Journal of the American Medical Association 1999; 281: 2127-37.
38. CDC, USA. Draft 2 - Annex 1. Overview of small pox, clinical presentations and medical care of small pox patients. Interim Smallpox Response Plan and Guidelines Annex 1: www.bt.cdc.gov/DocumentsApp/Smallpox/RPG/annex/annex-1-part1of3.pdf www.bt.cdc.gov/DocumentsApp/Smallpox/RPG/annex/annex-1-part2of3.pdf www.bt.cdc.gov/DocumentsApp/Smallpox/RPG/annex/annex-1-part3of3.pdf.
39. Public Health Laboratory Service - Communicable Disease Surveillance Centre. Interim Guidelines for Action in the Event of Deliberate Release, Smallpox (Version 3). Issued by Communicable Disease Surveillance Centre; 5 July 2002. http://www.phls.co.uk/topics_az/smallpox/smallpox_guidelines.pdf.
40. Deresiewicz RL, Thaler SJ, Hsu L. Clinical and neuroradiographic manifestations of eastern equine encephalitis. New England Journal of Medicine 1997; 336: 1867-74.
41. Golomb MR, Durand NIL, Schaefer PW, et al. A case of immunotherapy responsive eastern equine encephalitis with diffusion-weighted imaging. Neurology 2001; 56: 420-1.
42. Borio L, Inglesby TY, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons. Medical and public health management. Journal of the American Medical Association 2000; 287: 2391-405.
43. Chen JP, Cosgriff TM. Haemorrhagic fever virus induced changes in hemostasis and vascular biology. Blood Coagulation and Fibrinolysis 2000; 11: 461-83.
44. Aureli P, Fenicia L, Pasolini B, et al. Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyrricurn in Italy. Journal of Infectious Diseases 1986; 154: 207-11.
45. Hall JD, McCroskey LM, Pincomb BJ, et al. Isolation of an organism resembling clostridium barati which produces type F botulinal toxin from an infant with botulism. Journal of Clinical Microbiology 1985; 21: 654-5.
46. Schiavo G, Rossetto O, Benfenati F, Poulain B, Montecucco C. Tetanus and botulism neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Annals of the New York Academy of Medical Sciences 1994; 710: 65-75.
47. Arnon SS, Schecter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: Medical and public health management. Journal of the American Medical Association 2001; 285: 1059-70.
48. Sandrock CE, Murin S. Clinical predictors of respiratory failure and long term outcome in black tar heroin-associated wound botulism. Chest 2001; 120: 562-6.
49. Public Health Laboratory Service - Communicable Disease Surveillance. Interim Guidelines for Action in the Event of Deliberate Release, Botulism (Version 3). Issued by Communicable Disease Surveillance Centre; 23 November 2001. http://www.phls.co.uk/topics_az/botulism_guidelines/pdf.
50. Centers for Disease Control and Prevention. Botulism in the United States 1899-1996. Handbook for Epidemiologists, Clinicians and Laboratory Workers. Atlanta, GA: Centers for Disease Control and Prevention, 1998. http://www.cdc.gov/nciod/dbmd/diseascinfo/botulism.pdf.
51. Anon. Web site for US army medical personnel www.nbcmed.org/sitecontent/MedRef/onlineRef/FieldManuals/medman/Ricin.htm.
52. Oregon Department of Health Service/Oregon Health Division. http://www.ohd.hr.state.or.us/acd/bioterr/t2.pdf.
53. Anon. Web site for US army medical personnel http://www.nbc-med.org/sitecontent/MedRef/onlineRef/FieldManuals/medman/staphylo .htm.
54. Stiles BG, Bavari S, Krakauer T, Ulrich RG. Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependancy and cytokine release. Infection and Immunity 1993; 61: 5333-8.